Korean conglomerate SK takes out stake in cell and gene therapy CDMO with plans for a major hiring spree outside Philly
A Pennsylvania CDMO specializing in cell and gene therapy manufacturing is receiving a big influx of cash from a South Korean drugmaker — and it has plans for a major hiring spree.
SK, the holding company of SK bioscience, will invest $350 million of equity financing into the Center for Breakthrough Medicines, with plans to add an additional 2,000 employees as part of a redux at the CDMO’s King of Prussia, PA facility.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.